394 related articles for article (PubMed ID: 25400440)
1. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.
Sutton JM; Abbott DE
World J Gastroenterol; 2014 Nov; 20(42):15564-79. PubMed ID: 25400440
[TBL] [Abstract][Full Text] [Related]
2. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.
Breslin TM; Janjan NA; Lee JE; Pisters PW; Wolff RA; Abbruzzese JL; Evans DB
Front Biosci; 1998 Nov; 3():E193-203. PubMed ID: 9792895
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
6. Resection and radiochemotherapy of pancreatic cancer--the future?
Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.
Brown KM; Siripurapu V; Davidson M; Cohen SJ; Konski A; Watson JC; Li T; Ciocca V; Cooper H; Hoffman JP
Am J Surg; 2008 Mar; 195(3):318-21. PubMed ID: 18308038
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
Czosnyka NM; Borgert AJ; Smith TJ
HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
[TBL] [Abstract][Full Text] [Related]
9. Role of surgery in pancreatic cancer.
Buanes TA
World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216
[TBL] [Abstract][Full Text] [Related]
10. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
11. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
[TBL] [Abstract][Full Text] [Related]
12. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinoma of the pancreas: the rationale for neoadjuvant therapy.
Sperti C; Pasquali C; Pastorelli D; Ferronato A; Decet G; Pedrazzoli S
Acta Biomed; 2003; 74 Suppl 2():91-5. PubMed ID: 15055044
[TBL] [Abstract][Full Text] [Related]
14. Trends in the treatment of resectable pancreatic adenocarcinoma.
Raigani S; Ammori J; Kim J; Hardacre JM
J Gastrointest Surg; 2014 Jan; 18(1):113-23. PubMed ID: 24002769
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant and adjuvant therapy of ductal pancreatic carcinoma].
Hohenberger W; Kastl S
Zentralbl Chir; 2000; 125(4):348-55. PubMed ID: 10829315
[TBL] [Abstract][Full Text] [Related]
16. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
17. Optimal timing and treatment strategy for pancreatic cancer.
Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
[TBL] [Abstract][Full Text] [Related]
18. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
